Ion Beam Applications SA
XBRU:IBAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (8.8), the stock would be worth €12.04 (16% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.6 | €14.4 |
0%
|
| 3-Year Average | 8.8 | €12.04 |
-16%
|
| 5-Year Average | 8.9 | €12.06 |
-16%
|
| Industry Average | 12.3 | €16.68 |
+16%
|
| Country Average | 8.9 | €12.08 |
-16%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€389.4m
|
/ |
Jan 2026
€41.7m
|
= |
|
|
€389.4m
|
/ |
Dec 2026
€56.2m
|
= |
|
|
€389.4m
|
/ |
Dec 2027
€64.2m
|
= |
|
|
€389.4m
|
/ |
Dec 2028
€77.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
Ion Beam Applications SA
XBRU:IBAB
|
422.2m EUR | 10.6 | 33.2 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 14 | 25.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 42.5 | 56.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 12.7 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 18.2 | 30.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 11.3 | 20.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 23.4 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 30.3 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 10 | 25.4 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 11.4 | 15.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 5.6 |
| Median | 8.9 |
| 70th Percentile | 14 |
| Max | 598.6 |
Other Multiples
Ion Beam Applications SA
Glance View
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. The company is headquartered in Louvain-La-Neuve, Brabant-Wallon. IBA is also active in the sterilization and ionization field. The firm operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
